Pembrolizumab and Paclitaxel in Patients with HR+/HER2− Breast Cancer with HER2-Enriched or Basal-like Subtypes
Authors:
- Benedetta ConteBCBenedetta Conte
- Fara Brasó-MaristanyFBFara Brasó-Maristany
- Tomás PascualTPTomás Pascual
- Cristina HernandoCHCristina Hernando
- Silvia VázquezSVSilvia Vázquez
- Salvador BlanchSBSalvador Blanch
- Mafalda OliveiraMafalda Oliveira
- Juan Antonio VirizuelaJVJuan Antonio Virizuela
- Montserrat MuñozMMMontserrat Muñoz
- Elia SeguíESElia Seguí
- Adela Rodriguez-HernandezAdela Rodriguez-Hernandez
- Maria Jesus Vidal LosadaMLMaria Jesus Vidal Losada
Open Access
- 22 January 2026
- journal article
- Published by American Association for Cancer Research (AACR) in Clinical Cancer Research
- Vol. 32 (7) , 1246-1257
Abstract
Purpose: Hormone receptor–positive (HR+), HER2-negative (HER2−) metastatic breast cancer (mBC) is biologically distinct from early-stage disease, with a higher prevalence of genomically defined nonluminal subtypes, particularly the HER2-enriched (HER2-E) and basal-like subtypes. These tumors are highly proliferative, less dependent on hormone signaling, and associated with poor outcomes and early resistance to endocrine therapy and CDK4/6 inhibition (CDK4/6i). This biological shift highlights the need for biomarker-driven strategies in the CDK4/6i-resistant setting. Patients and Methods: The SOLTI-1716 TATEN trial (NCT04251169) is a phase II, single-arm study evaluating the combination of pembrolizumab and paclitaxel in patients with HR+/HER2− mBC classified as HER2-E or basal-like by PAM50 following progression on CDK4/6i. A total of 126 patients were screened using the PAM50 genomic assay; 20 with HER2-E or basal-like subtypes were enrolled and received pembrolizumab (200 mg every 3 weeks) and paclitaxel (80 mg/m2 weekly). Results: The primary endpoint, overall response rate (ORR), was 61.1% [95% confidence interval (CI), 35.7–82.7], and the clinical benefit rate was 94.4% (95% CI, 72.7–99.9). The median progression-free survival was 8.1 months (95% CI, 5.9–10.4), and the median overall survival was 26 months [95% CI, 18−not reached (NR)]. Three patients achieved durable responses lasting ≥24 months. Gene expression analyses revealed that high expression of proliferation- and immune-related genes predicted improved ORR and survival, whereas luminal-related gene expression was associated with lower clinical benefit. Conclusions: These results suggest that chemo-immunotherapy may be an effective strategy in genomically defined nonluminal subtypes of HR+/HER2− mBC following CDK4/6i resistance and highlight the value of molecular subtyping to guide post–endocrine treatment decisions.Keywords
All Related Versions
Funding Information
- HORIZON EUROPE Marie Sklodowska-Curie Actions (955951)
- Fundación Científica Asociación Española Contra el Cáncer (INVES21943BRAS)
- Fundación Científica Asociación Española Contra el Cáncer (EPAEC246711CLIN)
- Fundación Fero (ONCOXXI21)
- CRIS Cancer Foundation (PR_EX_2021-14)
- Instituto de Salud Carlos III (PI22/01017)
- Breast Cancer Research Foundation (BCRF-22-198)
- Breast Cancer Research Foundation (BCRF-23-198)
- Breast Cancer Research Foundation (BCRF-24-198)
- Horizon 2020 Framework Programme (847912)
This publication has 49 references indexed in Scilit:
- Post-progression treatment options after CDK4/6 inhibitors in hormone receptor-positive, HER2-negative metastatic breast cancerCancer Treatment Reviews, 2025
- TNBC-DX genomic test in early-stage triple-negative breast cancer treated with neoadjuvant taxane-based therapyAnnals of Oncology, 2024
- Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2− advanced breast cancer: final overall survival results of MONARCH 3Annals of Oncology, 2024
- Overall survival with palbociclib plus endocrine therapy versus capecitabine in postmenopausal patients with hormone receptor-positive, HER2-negative metastatic breast cancer in the PEARL studyEuropean Journal of Cancer, 2022
- Development and validation of the new HER2DX assay for predicting pathological response and survival outcome in early-stage HER2-positive breast cancerEBioMedicine, 2022
- ESMO Clinical Practice Guideline for the diagnosis, staging and treatment of patients with metastatic breast cancerAnnals of Oncology, 2021
- Pembrolizumab plus eribulin in hormone-receptor–positive, HER2-negative, locally recurrent or metastatic breast cancer (KELLY): An open-label, multicentre, single-arm, phase Ⅱ trialEuropean Journal of Cancer, 2021
- Effect of Eribulin With or Without Pembrolizumab on Progression-Free Survival for Patients With Hormone Receptor–Positive, ERBB2-Negative Metastatic Breast CancerJAMA Oncology, 2020
- The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2JAMA Oncology, 2020
- Prognostic Value of Intrinsic Subtypes in Hormone Receptor–Positive Metastatic Breast Cancer Treated With Letrozole With or Without LapatinibJAMA Oncology, 2016